LAB vs LLY · rev $174.4M vs P/E 39, rev $65.18B
Standard Biotools Inc (LAB) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
LAB currently screens at market cap $317.1M. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the LAB and LLY stock pages for the full models.
Not investment advice.